Similar articles for PMID: 18047178

Year	Number of Results
1970	1
1971	1
1980	1
1981	2
1984	2
1986	2
1989	1
1991	2
1992	2
1994	2
1995	1
1996	1
1997	1
1998	3
1999	3
2000	10
2001	1
2002	10
2003	6
2004	7
2005	7
2006	9
2007	15
2008	25
2009	11
2010	13
2011	19
2012	22
2013	23
2014	26
2015	26
2016	33
2017	28
2018	26
2019	27
2020	13
2021	15
2022	3

1

In vivo and in vitro evaluation of a solid dispersion system of gliclazide:PEG 6000.

Asyarie S, Rachmawati H. Asyarie S, et al. PDA J Pharm Sci Technol. 2007 Sep-Oct;61(5):400-10. PDA J Pharm Sci Technol. 2007. PMID: 18047178

2

Preparation and characterization of gliclazide-polyethylene glycol 4000 solid dispersions.

Patil MP, Gaikwad NJ. Patil MP, et al. Acta Pharm. 2009 Mar;59(1):57-65. doi: 10.2478/v10007-009-0001-3. Acta Pharm. 2009. PMID: 19304558 Free article.

3

Enhancement of dissolution rate of gliclazide using solid dispersions with polyethylene glycol 6000.

Biswal S, Sahoo J, Murthy PN, Giradkar RP, Avari JG. Biswal S, et al. AAPS PharmSciTech. 2008;9(2):563-70. doi: 10.1208/s12249-008-9079-z. Epub 2008 May 6. AAPS PharmSciTech. 2008. PMID: 18459056 Free PMC article.

4

In vitro evaluation and in vivo performance of lyophilized gliclazide.

Mansour HF, Aly UF. Mansour HF, et al. Drug Dev Ind Pharm. 2015 Apr;41(4):650-7. doi: 10.3109/03639045.2014.891131. Epub 2014 Feb 26. Drug Dev Ind Pharm. 2015. PMID: 24568609

5

Physicochemical characterization of gliclazide-macrogol solid dispersion and tablets based on optimized dispersion.

Khattab IS, Nada A, Zaghloul AA. Khattab IS, et al. Drug Dev Ind Pharm. 2010 Aug;36(8):893-902. doi: 10.3109/03639040903578734. Drug Dev Ind Pharm. 2010. PMID: 20196643

6

In vitro and in vivo studies on a novel solid dispersion of repaglinide using polyvinylpyrrolidone as the carrier.

Yin LF, Huang SJ, Zhu CL, Zhang SH, Zhang Q, Chen XJ, Liu QW. Yin LF, et al. Drug Dev Ind Pharm. 2012 Nov;38(11):1371-80. doi: 10.3109/03639045.2011.652635. Epub 2012 Feb 2. Drug Dev Ind Pharm. 2012. PMID: 22296267

7

Effect of binary and ternary solid dispersions on the in vitro dissolution and in-situ rabbit intestinal absorption of gliclazide.

El-Maghraby GM, Alomrani AH. El-Maghraby GM, et al. Pak J Pharm Sci. 2011 Oct;24(4):459-68. Pak J Pharm Sci. 2011. PMID: 21959805

8

A novel asymmetric membrane osmotic pump capsule with in situ formed delivery orifices for controlled release of gliclazide solid dispersion system.

Yang Y, Zhao Z, Wang Y, Yang L, Liu D, Yang X, Pan W. Yang Y, et al. Int J Pharm. 2016 Jun 15;506(1-2):340-50. doi: 10.1016/j.ijpharm.2016.04.061. Epub 2016 Apr 27. Int J Pharm. 2016. PMID: 27132166

9

Amorphous solid dispersion of berberine with absorption enhancer demonstrates a remarkable hypoglycemic effect via improving its bioavailability.

Zhaojie M, Ming Z, Shengnan W, Xiaojia B, Hatch GM, Jingkai G, Li C. Zhaojie M, et al. Int J Pharm. 2014 Jun 5;467(1-2):50-9. doi: 10.1016/j.ijpharm.2014.03.017. Epub 2014 Mar 5. Int J Pharm. 2014. PMID: 24607213

10

Development and characterization of lecithin stabilized glibenclamide nanocrystals for enhanced solubility and drug delivery.

Kumar BS, Saraswathi R, Kumar KV, Jha SK, Venkates DP, Dhanaraj SA. Kumar BS, et al. Drug Deliv. 2014 May;21(3):173-84. doi: 10.3109/10717544.2013.840690. Epub 2013 Oct 9. Drug Deliv. 2014. PMID: 24102185

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed